share_log

We Think That There Are More Issues For Andon Health (SZSE:002432) Than Just Sluggish Earnings

We Think That There Are More Issues For Andon Health (SZSE:002432) Than Just Sluggish Earnings

我們認爲,安登健康(SZSE:002432)面臨的問題不僅僅是收益疲軟
Simply Wall St ·  05/08 18:38

Last week's earnings announcement from Andon Health Co., Ltd. (SZSE:002432) was disappointing to investors, with a sluggish profit figure. We did some further digging and think they have a few more reasons to be concerned beyond the statutory profit.

安登健康有限公司(SZSE:002432)上週的業績公告令投資者失望,盈利數字低迷。我們進行了進一步的挖掘,認爲除了法定利潤外,他們還有其他一些值得關注的理由。

earnings-and-revenue-history
SZSE:002432 Earnings and Revenue History May 8th 2024
SZSE: 002432 收益和收入歷史記錄 2024 年 5 月 8 日

The Impact Of Unusual Items On Profit

不尋常物品對利潤的影響

To properly understand Andon Health's profit results, we need to consider the CN¥71m gain attributed to unusual items. While it's always nice to have higher profit, a large contribution from unusual items sometimes dampens our enthusiasm. When we analysed the vast majority of listed companies worldwide, we found that significant unusual items are often not repeated. Which is hardly surprising, given the name. Assuming those unusual items don't show up again in the current year, we'd thus expect profit to be weaker next year (in the absence of business growth, that is).

爲了正確了解安登健康的利潤業績,我們需要考慮不尋常項目帶來的7100萬元人民幣的收益。雖然獲得更高的利潤總是件好事,但來自不尋常物品的巨額捐款有時會抑制我們的熱情。當我們分析全球絕大多數上市公司時,我們發現重大不尋常的事項往往不會重演。考慮到這個名字,這並不奇怪。假設這些不尋常的項目在本年度不會再次出現,因此我們預計明年的利潤將疲軟(也就是說,在業務沒有增長的情況下)。

Note: we always recommend investors check balance sheet strength. Click here to be taken to our balance sheet analysis of Andon Health.

注意:我們始終建議投資者檢查資產負債表的實力。點擊此處查看我們對安登健康的資產負債表分析。

Our Take On Andon Health's Profit Performance

我們對安登健康利潤表現的看法

We'd posit that Andon Health's statutory earnings aren't a clean read on ongoing productivity, due to the large unusual item. Therefore, it seems possible to us that Andon Health's true underlying earnings power is actually less than its statutory profit. But the good news is that its EPS growth over the last three years has been very impressive. At the end of the day, it's essential to consider more than just the factors above, if you want to understand the company properly. In light of this, if you'd like to do more analysis on the company, it's vital to be informed of the risks involved. In terms of investment risks, we've identified 2 warning signs with Andon Health, and understanding them should be part of your investment process.

我們認爲,由於這個很大的不尋常項目,Andon Health的法定收入並不能完全反映持續的生產率。因此,在我們看來,Andon Health的真正潛在盈利能力實際上可能低於其法定利潤。但好消息是,其在過去三年中的每股收益增長非常令人印象深刻。歸根結底,如果你想正確地了解公司,必須考慮的不僅僅是上述因素。有鑑於此,如果你想對公司進行更多分析,了解所涉及的風險至關重要。在投資風險方面,我們已經向Andon Health確定了兩個警告信號,了解它們應該是您投資過程的一部分。

Today we've zoomed in on a single data point to better understand the nature of Andon Health's profit. But there is always more to discover if you are capable of focussing your mind on minutiae. Some people consider a high return on equity to be a good sign of a quality business. While it might take a little research on your behalf, you may find this free collection of companies boasting high return on equity, or this list of stocks that insiders are buying to be useful.

今天,我們放大了單一數據點,以更好地了解安登健康利潤的性質。但是,如果你能夠將注意力集中在細節上,總會有更多的事情需要發現。有些人認爲高股本回報率是優質業務的好兆頭。雖然可能需要你進行一些研究,但你可能會發現這份免費收集的擁有高股本回報率的公司,或者這份內部人士正在購買的股票清單很有用。

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

對這篇文章有反饋嗎?對內容感到擔憂?直接聯繫我們。 或者,給編輯團隊 (at) simplywallst.com 發送電子郵件。
Simply Wall St的這篇文章本質上是籠統的。我們僅使用公正的方法根據歷史數據和分析師的預測提供評論,我們的文章無意作爲財務建議。它不構成買入或賣出任何股票的建議,也沒有考慮到您的目標或財務狀況。我們的目標是爲您提供由基本數據驅動的長期重點分析。請注意,我們的分析可能不考慮最新的價格敏感型公司公告或定性材料。簡而言之,華爾街沒有持有任何上述股票的頭寸。

声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論